366 related articles for article (PubMed ID: 28092499)
1. Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy.
Babu A; Muralidharan R; Amreddy N; Mehta M; Munshi A; Ramesh R
IEEE Trans Nanobioscience; 2016 Dec; 15(8):849-863. PubMed ID: 28092499
[TBL] [Abstract][Full Text] [Related]
2. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
Hatakeyama H; Wu SY; Mangala LS; Lopez-Berestein G; Sood AK
Methods Mol Biol; 2016; 1402():189-197. PubMed ID: 26721492
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic siRNA: principles, challenges, and strategies.
Gavrilov K; Saltzman WM
Yale J Biol Med; 2012 Jun; 85(2):187-200. PubMed ID: 22737048
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?
Aghamiri S; Mehrjardi KF; Shabani S; Keshavarz-Fathi M; Kargar S; Rezaei N
Nanomedicine (Lond); 2019 Aug; 14(15):2083-2100. PubMed ID: 31368405
[TBL] [Abstract][Full Text] [Related]
5. A Review of pH-Responsive Organic-Inorganic Hybrid Nanoparticles for RNAi-Based Therapeutics.
Wang L; Yan Y
Macromol Biosci; 2021 Sep; 21(9):e2100183. PubMed ID: 34160896
[TBL] [Abstract][Full Text] [Related]
6. Functional nanostructures for effective delivery of small interfering RNA therapeutics.
Hong CA; Nam YS
Theranostics; 2014; 4(12):1211-32. PubMed ID: 25285170
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy.
Miele E; Spinelli GP; Miele E; Di Fabrizio E; Ferretti E; Tomao S; Gulino A
Int J Nanomedicine; 2012; 7():3637-57. PubMed ID: 22915840
[TBL] [Abstract][Full Text] [Related]
8. RNAi-based therapeutics and tumor targeted delivery in cancer.
Kara G; Calin GA; Ozpolat B
Adv Drug Deliv Rev; 2022 Mar; 182():114113. PubMed ID: 35063535
[TBL] [Abstract][Full Text] [Related]
9. Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery.
Kim B; Park JH; Sailor MJ
Adv Mater; 2019 Dec; 31(49):e1903637. PubMed ID: 31566258
[TBL] [Abstract][Full Text] [Related]
10. Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo.
Lee SJ; Yook S; Yhee JY; Yoon HY; Kim MG; Ku SH; Kim SH; Park JH; Jeong JH; Kwon IC; Lee S; Lee H; Kim K
J Control Release; 2015 Dec; 220(Pt B):631-41. PubMed ID: 26307351
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
12. A RNA nanotechnology platform for a simultaneous two-in-one siRNA delivery and its application in synergistic RNAi therapy.
Jang M; Han HD; Ahn HJ
Sci Rep; 2016 Aug; 6():32363. PubMed ID: 27562435
[TBL] [Abstract][Full Text] [Related]
13. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
[TBL] [Abstract][Full Text] [Related]
14. Ultra-pH-Responsive and Tumor-Penetrating Nanoplatform for Targeted siRNA Delivery with Robust Anti-Cancer Efficacy.
Xu X; Wu J; Liu Y; Yu M; Zhao L; Zhu X; Bhasin S; Li Q; Ha E; Shi J; Farokhzad OC
Angew Chem Int Ed Engl; 2016 Jun; 55(25):7091-7094. PubMed ID: 27140428
[TBL] [Abstract][Full Text] [Related]
15. Direct cytoplasmic delivery of RNAi therapeutics through a non-lysosomal pathway for enhanced gene therapy.
Zhou J; Zhang J; Chen S; Lin Q; Zhu R; Wang L; Chen X; Li J; Yang H
Acta Biomater; 2023 Oct; 170():401-414. PubMed ID: 37625679
[TBL] [Abstract][Full Text] [Related]
16. Folate Receptor-Mediated siRNA Delivery: Recent Developments and Future Directions for RNAi Therapeutics.
Gangopadhyay S; Nikam RR; Gore KR
Nucleic Acid Ther; 2021 Aug; 31(4):245-270. PubMed ID: 33595381
[TBL] [Abstract][Full Text] [Related]
17. Targeted Liposomes for siRNA Delivery to Cancer.
Eloy JO; Petrilli R; Raspantini GL; Lee RJ
Curr Pharm Des; 2018; 24(23):2664-2672. PubMed ID: 30084323
[TBL] [Abstract][Full Text] [Related]
18. Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy.
Mainini F; Eccles MR
Molecules; 2020 Jun; 25(11):. PubMed ID: 32532030
[TBL] [Abstract][Full Text] [Related]
19. Recent developments in nanoparticle-based siRNA delivery for cancer therapy.
Lee JM; Yoon TJ; Cho YS
Biomed Res Int; 2013; 2013():782041. PubMed ID: 23844368
[TBL] [Abstract][Full Text] [Related]
20. RNA interference technology with emphasis on delivery vehicles-prospects and limitations.
Prabha S; Vyas R; Gupta N; Ahmed B; Chandra R; Nimesh S
Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1391-9. PubMed ID: 26140615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
